

Trials ongoing but closed to recruitment

1. IMR-687: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle- β 0 Thalassaemia) (closed to recruitment)

Imara IMR-687 is an oral medication that uniquely targets both the red blood cell and white blood cell aspects of the sickle cell disease, there is an ongoing clinical trial which is assessing the effect of the medication in sickle cell disease. The study recruited 100 adults with sickle cell disease aged between 18 and 55 for Kings College, Guys and St Thomas as well as Lewisham University Hospital.

The early phase of the trial has closed to recruitment but participants are finishing their study visits at present and we will update this website with the study findings when available

2. HESTIA 3 Clinical Trial (study Terminated)

Ticagrelor (BRILINTA™) is an oral anti platelet medication being used in a clinical trial to assess the effect of the medication in sickle cell disease. It was an international, multicentre, double-blind, randomised, parallel-group, placebo-controlled Phase III study to evaluate the effect of ticagrelor versus placebo in reducing the rate of VOCs in paediatric patients with SCD . During the treatment period, patients were monitored for occurrence of VOCs and other acute SCD complications.

The study terminated early and we will update this website with the study findings when available

3. A Study of the effect of IW-1701(Olinciguat), a stimulator of soluble Guanylate(sGC), on Patients with Sickle Cell Disease (SCD)

Olinciguat is a once a day tablet which works by stimulating an enzyme called soluble guanylate cyclase which plays a key role in production of nitric oxide, a free radical that promotes blood flow and is depleted when red blood cells rupture in people with sickle cell disease.

This study successfully recruited 70 SCD patients and has now closed to we will update this website with the study findings when available